VIR BIOTECHNOLOGY, INC. (VIR): Price and Financial Metrics


Today's Latest Price: $37.27 USD

2.70 (7.81%)

Updated Oct 22 4:00pm

Add VIR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

VIR Stock Price Chart Interactive Chart >

Price chart for VIR

VIR Price/Volume Stats

Current price $37.27 52-week high $75.00
Prev. close $34.57 52-week low $11.65
Day low $36.56 Volume 1,260,900
Day high $38.43 Avg. volume 1,185,952
50-day MA $38.44 Dividend yield N/A
200-day MA $35.50 Market Cap 4.74B


Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA.

VIR Latest News Stream

Event/Time News Detail
Loading, please wait...

VIR Latest Social Stream

Loading social stream, please wait...

View Full VIR Social Stream

Latest VIR News From Around the Web

Below are the latest news stories about Vir Biotechnology Inc that investors may wish to consider to help them evaluate VIR as an investment opportunity.

Goldman Sachs Upgrades Vir Biotechnology to Buy, Raises Price Target to $54

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …

Benzinga | September 14, 2020

Thinking about trading options or stock in Immunomedics, Oracle, Vir Biotechnology, United Airlines, or Tesla?

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMU, ORCL, VIR, UAL, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…

PR Newswire | September 14, 2020

Vir Biotechnology Appoints Janet Napolitano to its Board of Directors

SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board…

GlobeNewswire | September 1, 2020

Vir, GlaxoSmithKline Begin Phase 2/3 Study of Covid-19 Treatment

By Matt Grossman Vir Biotechnology Inc. and GlaxoSmithKline Plc have dosed the first patient in a Phase 2/3 study of the use of a…

ADVFN UK | August 31, 2020

Vir Biotechnology EPS beats by $0.35, beats on revenue

Vir Biotechnology (VIR): Q2 GAAP EPS of -$0.27 beats by $0.35.Revenue of $66.99M (+3167.8% Y/Y) beats by $63.09M.License granted to GSK under the collaboration agreement of $43.3M and $22.7M from Brii Biosciences.Press Release...

Seeking Alpha | August 11, 2020

Read More 'VIR' Stories Here

VIR Price Returns

1-mo 11.49%
3-mo -22.45%
6-mo 14.29%
1-year 160.63%
3-year N/A
5-year N/A
YTD 196.38%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6522 seconds.